zurück

Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C

Subject:

Active Substance: Sofosbuvir, Ledipasvir/Sofosbuvir, Simeprevir, Daclatasvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir
Name: SOVALDI^®, HARVONI^®, OLYSIO^™, DAKLINZA^™, VIEKIRAX^®, EXVIERA^®
Therapeutic area: Hepatitis C
Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA, AbbVie Deutschland GmbH & Co. KG, Janssen-Cilag GmbH, Gilead Sciences GmbH

Time table:

Assessment information:

Title: Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C
Author/Co-Author: KCE (Belgium), AAZ (Croatia), UCSC Gemelli (Italy), HVB (Austria)
Dedicated Reviewers: SNHTA (Switzerland), SAGEM HTA (Turkey), ZIN (Netherlands), AETSA (Spain), AIFA (Italy), MoH Slovak Republic (Slovakia), NIPHNO (Norway), HAS (France), MoH Malta (Malta), NVD (Latvia), FIMEA (Finland), SMC (Scotland), IQWiG (Germany), INFARMED (Portugal)